Find a Physician | How to Contribute | Contact Us | Clinical Trials
Search: 
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Clinical Trial NU 13S02

Title
Multicenter, Open-Label Phase II Study of Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
Principal Investigator
Mark Agulnik
Details
  • Status: Accepting New Patients
  • Study Type: Therapeutic, Treatment
  • Protocol No:.NU 13S02
Purpose
The purpose of this study is to see whether a drug called regorafenib might be effective in treating angiosarcoma.
Overview
This study is for patients who have a type of cancer called angiosarcoma that has gotten worse after they received chemotherapy. Regorafenib is a type of drug called a kinase inhibitor. Kinases are proteins (large molecules made up of various amino acids) on cells that send important signals to the cell’s control center. Regorafenib interferes with how some of these kinase proteins work. Some of these kinases in cancer cells might normally help the cancer cells grow or form new blood vessels that could feed a growing tumor. By blocking these proteins, regorafenib may help stop the growth of certain cancers. Regorafenib is currently approved by the Food and Drug Administration (FDA) for the treatment of certain cancers including colorectal cancer and gastrointestinal stromal tumors. Regorafenib is not approved by the FDA to treat angiosarcomas; therefore, its use in this study is considered investigational.
Eligibility
Some of the eligibility criteria include:
  • Participants must have angiosarcoma that may not be removed with surgery.
  • Participants must have cancer that has gotten worse after prior chemotherapy.
  • Participants may not have had sorafenib treatment in the past.
  • Participants must be 18 or older.
Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Description of Treatment
Participants in this study will take the study drug, regorafenib, by mouth every day for 21 days straight, followed by a 7 day break during which the study drug will not be taken. This is called a treatment cycle and the duration of each cycle is 4 weeks. The study doctor will reassess the participant's cancer after every 2 cycles of treatment (approximately every 8 weeks). Participants will continue to receive study treatment until their cancer gets worse, they experience unacceptable side effects, or they and/or the doctor feel it is in their best interest to stop.
Contact
Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
312.695.1102
cancertrials@northwestern.edu

Find Related Clinical Trials

Browse by Disease Sites

Other Clinical Trials by Mark Agulnik

last updated: 25-Oct-14 12:30 AM

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.